Novo Nordisk invests $74M to boost API manufacturing for clinical trials

With all the talk of drugmakers trimming back pipelines and laying off staff, it’s good to occasionally report on some more expansionist plans across the sector. For Novo Nordisk, that means investing 5.4 billion Danish kroner ($74 million) to boost R&D manufacturing needed to support its clinical trials.